Bronchiolitis obliterans syndrome (BOS) is a serious complication of chronic GVHD (cGVHD) following HSCT (hematopoietic SCT). The clinical diagnosis of BOS is based on pulmonary function test (PFT) abnormalities including: FEV1o75% predicted and obstructive FEV1/VC ratio, calculated using reference equations. We sought to determine if the frequency of clinical diagnoses and severity of BOS would be altered by using the recommended NHANES III vs older equations (Morris/Goldman/Bates, MGB) in 166 cGVHD patients, median age 48 (range: 12-67). We found that NHANES III equations significantly increased the prevalence of BOS, with an additional 11% (18/166) meeting diagnostic criteria by revealing low FEV1 (o75%) (Po0.0001), and six additional patients by obstructive ratio (vs MBG). Collectively, this led to an increase of BOS incidence from 17 (29/166) to 29% (41/166). For patients with severe BOS, (FEV1o35%), NHANES III equations correctly predicted death 71.4% vs 50% using MGB. In conclusion, the use of NHANES III equations markedly increases the proportion of cases meeting diagnostic criteria for BOS and improves prediction of survival.
INTRODUCTION
Bronchiolitis obliterans syndrome (BOS) after HSCT is an insidious disease with a poor outcome whereby the donor immune system attacks the small airways in the lungs (also known as chronic GVHD (cGVHD) of the lung), leading to obstructive pulmonary disease and air trapping. 1 Although occurring in only 5-7% patients after HSCT only 44% of BOS patients are expected to survive 2 years, a dismal prognosis which remains unchanged in the last 30 years. [2] [3] [4] Delay in diagnosis is thought to contribute to inferior outcomes because symptoms develop late in the disease course. As HSCTs are becoming safer and the number of patients undergoing transplantation increases, this once rare disease will affect more individuals, 5, 6 increasing the need for accurate diagnosis to alter treatment and potentially improve outcomes.
Although open lung biopsy has high sensitivity and specificity for BO, it has an unacceptable rate of complications. [7] [8] [9] [10] Currently, early BOS diagnosis relies on recognition of decline in both FEV1 and FEV1/VC, 1,11 the identifying hallmark of: airflow obstruction. 12 The NIH consensus group diagnostic criteria for lung cGVHD (BOS, 2005) 13, 14 have been refined to focus BOS diagnosis on the FEV1 and ratio of FEV1/vital capacity, 1, 6, 15, 16 rather than mandating elevated residual volume and air trapping on computed tomography (CT), which are late findings of disease and will thus contribute to later diagnosis.
The reference equations used to calculate %predicted for pulmonary function tests (PFTs) are generated from population surveys and have shown that PFT interpretations depend upon race, height, age and gender. 17 The reference equations have changed over time as new studies have suggested more stringent criteria for the definition of 'normal' to be included in the population survey and included more patients in the population surveys. Older reference equations, such as those generated by Morris, Goldman and Bates, often included smokers or ex-smokers, yielding lower 'normal values' for lung function. In addition, there were less stringent criteria for the reproducibility of the test and often fewer individuals of differing genders and races, limiting the sample size for the calculation of normal for these groups. 18 The NHANES III reference equations, derived from PFTs of over 20 000 healthy Americans, are currently the equations recommended by both the American and European Thoracic Societies; however, institutions use older equations due to cost constraints. 17 Limited data have been published comparing these equations 19, 20 and explore whether different equations might influence the diagnosis and characterization of severity of BOS after HSCT. This could have implications for individual patient guidance about disease severity, comparison between published patients, and for normalization in multi-center trials in this disease.
Given these findings, we hypothesized that the newer reference equations might alter the proportion of patients who meet the diagnostic criteria for BOS in a cGVHD cohort, as the diagnosis of BOS relies upon a decline in FEV1 o75% predicted and the discrimination of normal vs obstructed ratio (FEV1/forced vital capacity (FVC)). Both of these are dependent upon the equation used. Although the majority of patients with a ratio less than this cutoff will have obstructive disease, two groups of patients are potentially misclassified by this threshold. 21 First, younger patients may have higher ratios at baseline because the ratio declines naturally with age. Thus, a young patient will need a more severe decline in FEV1 to demonstrate obstruction using this cutoff. The NHANES III equations include the confidence interval (CI), adjusting for age. In chronic obstructive pulmonary disease (COPD), the use of the FEV1/FVC o0.7 cutoff rather than the lower limit of normal led to nearly 50% of smoking young adults misclassified as normal rather than obstructed, 22 hindering diagnosis in this age group. Furthermore, older individuals may have a lower ratio that should be classified as normal secondary to advanced age. In smoking older individuals, 20% were misclassified as obstructed using MGB while still within the range of normal for the ratio using NHANES III. 22 Notably, these findings were not observed in healthy, non-smoking individuals suggesting that different pathologies may lead to differences in degree and direction of discordance. Given the severity of BOS and the potential emerging therapies for this disease, it is important to distinguish those with the disease from those who have alterations expected for age and to avoid delays in diagnosis secondary to artificial threshold values for obstruction that may not be applicable to younger individuals.
Thus, we evaluated whether use of the NHANESIII reference equations for PFT interpretation altered the number of patients who met clinical criteria for diagnosis of BOS in a cGVHD cohort as compared with the older equations (MGB), and whether the altered values correlated with disease severity and predicted mortality in this cohort.
MATERIALS AND METHODS
Data for this cross-sectional study (n ¼ 180) were obtained from sequentially recruited adults participating in a natural history study of survivors of allogeneic HSCT with cGVHD (clinicaltrials.gov#NCT00331968, initiated 2004), and 166 were analyzed, after excluding 14 subjects without PFT data. Patients are enrolled following self and primary clinician referrals and undergo a series of specialist evaluations over the course of a week (including ophthalmology, oral medicine, pulmonary, dermatology and rehabilitation medicine) that includes a full characterization of cGVHD manifestations; this cohort has been published in part in prior manuscripts addressing different manifestations. [23] [24] [25] Because this is a protocol with predominantly outside referrals, this population is enriched for patients with severe cGVHD (460%). NIH consensus evaluations included the lung symptom score; lung symptom score is calculated as follows: FEV1% predicted and DLC02 adjusted % predicted are ranked by 480% ¼ 1, 70-79% ¼ 2, 60-69% ¼ 3, 50-59% ¼ 4, 40-49% ¼ 5, o40% ¼ 6 and a sum generated from these rankings for FEV1 and DLCO2 with a score of: normal: 2, mild decrease: 3-5, moderate decrease: 6-9, severe decrease: 10-12. 13, 14 Missing data for cGVHD categories was o5%. Notably, the charts of patients who were diagnosed as BOS were pulled and evaluated for other PFTs (at least one) that revealed ongoing obstructive lung disease and absence of infection at the time of diagnosis.
PFTs were performed following American Thoracic Society (ATS) standards. 17 Comparison was then performed using MGB and NHANESIII equations.
Statistical methods
The classification of FEV1% o75% vs 475% predicted and FEV1/FVC o0.7 vs X0.7 were assessed for extent of agreement using McNemar's exact test for paired categorical data. The characterization of obstruction using the fifth percentile threshold (NHANES III) was also evaluated in a similar fashion using the same method. On the basis of sensitivity data, FEV1 of 40% 26 and 35% 21 predicted were used to predict oxygen requirement and mortality, respectively. The correlation between FEV1 and 2-min walk velocity was determined by Spearman rank correlation analysis, with |r| o0.30 being considered weak correlation. Overall survival between patients with and without BOS was compared by two-tailed log-rank test. In addition, mortality by 1 year was compared according to FEV1 p35% vs 435% using Fisher's exact test. All P-values are two-tailed, and as this is intended to be a descriptive and hypothesis generating study, are reported without any adjustment for the number of tests performed.
Medical records, Social Security Death Index, phone calls to patients and contacting referring physicians offices were used to determine participant vital status (captured for the cohort within the database from prior publications). 23 In this paper, mortality reflects all-cause mortality. All BOS patients had at least 1-year follow-up (that is, enrolled X1 year prior to analysis).
RESULTS

Patient characteristics by history, symptoms and cGVHD categorization
The cohort (n ¼ 166) was evenly divided in terms of gender, myeloablative regimen and predominantly Caucasian (Table 1) . Most patients (89%) were characterized as classic chronic GVHD and had experienced progressive disease from acute GVHD. Although the majority of patients (60%) had severe cGVHD disease in terms of global NIH cGVHD score and 72% reported lung symptoms, only 27% were moderate or severe (including limitations defined by shortness of breath with walking on flat ground or at rest). Notably, these descriptions of disease severity were scored using the older equations (MBG) as these were the equations in use at the time of study enrollment.
MGB and NHANESIII equations altered the number of patients identified with reduced FEV1% predicted and obstructive ratio significantly NHANESIII reference equations significantly altered the number of cGVHD patients with an abnormal (FEV1o75% predicted), with 11% (18/166) misclassified as normal by MGB, yet abnormal by NHANES III (Po0.0001, Figure 1 ). In contrast, no patients with normal FEV1% predicted by NHANES III were abnormal by MGB. Thus, using NHANESIII to reclassify patients by FEV1% predicted was exclusively in the direction of diminished values as compared with MGB, increasing from 60 to 78 the number of patients who met one key element of the clinical criteria necessary for BOS diagnosis. The median difference in FEV1% predicted between MGB and NHANES III interpretation was 7%, with the largest discrepancy in absolute % predicted of 27% in non-BOS patients (from 110 (MGB) to 83% (NHANES III)) and 12% in BOS patients (from 83% (MBG) to 71% (NHANES III)). NHANES III reference equations include a range for normal FEV1/VC with a CI below which the diagnosis of obstruction is made, which should be more accurate than a strict threshold value. Using this CI threshold rather than the 0.7 cutoff (with MGB) to identify obstruction, resulted in the diagnosis of BOS in six additional patients who had a normal FEV/FVC ratio by MGB. As expected because the ratio declines with age, those patients who were misclassified by MGB and captured as obstructive with NHANES III CI were younger (median 21.5, range 21-28 years). Only one patient was misclassified as obstructed using MGB when the NHANESIII CI was applied, and as predicted, this was an elderly patient thus 0.7 was within the normal range for age. Thus, use of NHANESIII equations increased the number of patients with abnormal FEV1% predicted and better identified those with abnormal FEV1/VC.
MBG and NHANESIII equations significantly altered the number of patients clinically diagnosed with BOS Given the altered numbers of patients now classified as abnormal FEV1 and obstructive disease using the CI of the ratio, the final number of patients clinically diagnosed with BOS was altered. Using the MGB reference equations for ratio and FEV1, and the current definition of BOS, 15 17% of the cGVHD cohort (29/166) were clinically diagnosed with BOS. When NHANESIII reference equations were used to calculate the FEV1% predicted and the CI for FEV1/FVC, 21% (35/166) of the patients meet criteria for BOS diagnosis (and 1 patient is removed because the decreased ratio is normal for advanced age) (Figure 2 ). Because patients with more advanced disease may have reduced FVC due to early collapse of the airway, the CI of the FEV1/VC (including the slow vital capacity) was calculated by NHANES III, leading to (41/166) 25% diagnosed with BOS of the cGVHD cohort ( Figure 2 ) and 1 patient was removed because the decreased ratio is normal for advanced age. The increase in diagnosis of BOS included patients both with mild and severe disease for distinct reasons. Patients were captured with more mild disease because NHANES III equations revealed early FEV1 declines (maximum difference of 13%). These patients were likely diagnosed in an earlier phase of disease, exemplified by the median FEV1 of 70% predicted for these newly captured patients vs 46% for the BOS cohort as a whole. In contrast, those patients now diagnosed using the CI of the FEV1/VC included more advanced patients with air trapping (reduced FVC), with a median FEV1 of 37.5% (Figure 3) . NHANESIII reference equations suggested improved prediction of oxygen requirement in BOS patients but not 2-min walk velocity To evaluate whether NHANESIII equations could be used to predict morbidity, we assessed the correlation of FEV1% predicted with both 2-min walk velocity and oxygen requirement. The 2-min walk velocity is recommended by NIH consortium to characterize cGVHD severity. 13 Correlations between FEV1 and 2-min walk velocity calculated by either method were weak and comparable (MGB (r ¼ 0.25) or NHANESIII (r ¼ 0.24)) (data not shown). Although only nine patients required supplemental oxygen, limiting the ability to draw conclusions, there was a suggestion that FEV1% predicted calculated by NHANESIII correlated with a requirement for oxygen. Within the patients who required oxygen supplementation, using FEV1% predicted o40%, previously determined to be the best threshold for positive predictive value and specificity of oxygen requirements, 26 (Figure 4 ). In contrast, using NHANES III equations revealed that death is more likely to occur with severe disease (8 died/9 with FEV1 o35% and only 4 died/22 with FEV1 435%). Similarly, adding the CI of the ratio to distinguish between equations to predict death, only 13% of those with mild/moderate FEV1 by NHANESIII died vs 21% in the MGB mild/moderate cohort. Thus, patients who died were more accurately categorized as severe by NHANES III (Figure 4 ). As expected, FEV1 o35% was a significant predictor of mortality with either equation: 7/7 with FEV1 o35% by MGB died within the first year while 27/34 (79%) with FEV1X35% remain alive (P ¼ 0.0002), and 10/11 (91%) with FEV1 o35% by NHANES have died vs 26/30 (87%) with FEV1 435% who remain alive (Po0.0001). However, the NHANES III equation correctly predicted death in 71.4% compared with 50% of patients when MGB equations were used. Thus, BOS severity categorized using NHANES III reference equations better correlated with survival.
DISCUSSION
BOS after HSCT confers a dismal prognosis that has been unchanged in the last 30 years. [2] [3] [4] It is believed that diagnosis in later stages of disease contributes to this poor prognosis. Ways to improve diagnostic sensitivity and specificity for BOS after HSCT could thus be important for improving outcomes. Recent data have revealed that decline in PFT parameters was the best way to identify children at risk for BOS 27 and support prior publications in adults. 1 The importance of FEV1 in the characterization of the severity of BOS is long established. FEV1 decline is a critical element of the definition of BOS and also is the most specific marker of obstruction, 2,12,15,28 best differentiating severe from mild or moderate disease. We thus attempted to correlate this marker of disease severity as determined by both reference equations with other indicators of disease severity.
This study was limited by cross-sectional design, small sample size of BOS patients, few biopsy-proven BOS cases, and relatively limited diversity of age and ethnicity for the cohort. This study was also limited by the potential for lack of specificity in BOS diagnosis and potential inclusion of patients without BOS. Although each patient diagnosed with BOS had a specific chart review to ascertain at least one other PFT that revealed obstructive lung disease, it is possible that patients are included in the BOS cohort who could rather have other diseases with similar PFT findings, to include COPD, infections or Alpha 1 anti-trypsin. Because of the cross-sectional design, these data rely upon a single PFT measurement, not a slope of decline that would be better to evaluate the influence of PFT measurements on outcomes. In addition, because cause of death was not collected in this protocol, the interpretation of the association of death with FEV1% predicted by equations was limited by inability to attribute cause of death. Our analyses should be replicated in a larger, more diverse cohort.
Using the amended consensus definitions for BOS, 1, 6, 15, 16 we demonstrate that the new NHANES III reference equations, significantly alter the number of patients meeting criteria for BOS diagnosis after HSCT, increasing the BOS cohort by 29% in our cGVHD population compared with older equations. Furthermore, these newly identified patients were clinically indistinguishable from those identified by older equations in terms of morbidity (oxygen requirement) and mortality. These additional patients identified using NHANES III equations met the BOS diagnostic criteria in one of two ways, either by capturing patients with early Figure 3 . Severity of patients who 'newly' met BOS diagnostic criteria using NHANES III equations. As compared with the FEV1% predicted of the total cohort (by NHANES III), those who 'newly' met BOS diagnostic criteria due to FEV1 decline (to o75%) revealed by NHANES III were mild as compared with the cohort. Patients identified because of inclusion of the SVC and CI were more severe (with FEV1% predicted less than the cGVHD total cohort). Figure 4 . Mortality of BOS patients with respect to severity by FEV1% predicted. On the Y axis is the number of patients who died and on the X axis, the BOS cohort is divided into two main groups:
(1) the older definitions including those with FEV1 o75% predicted and a ratio of FEV1/FVC o0.7 threshold for identification of BOS and (2) newer definitions including those with FEV1 o75% predicted and a ratio with FEV1/VC o0.7 or the ratio met criteria for obstruction with less than fifth percentile. For all cause mortality on this study, NHANES III equations better categorized these patients as very severe (FEV1o35%) using either the older or newer diagnostic criteria for BOS (with the largest proportion of severe BOS patients (black) defined by NHANES III).
disease through more sensitive detection of FEV1% decline or by capturing those who had more advanced disease and meet the criteria because NHANES III equations reveal obstruction that was masked using a strict threshold value for the FEV1/VC ratio. The older equations use a ratio cutoff for diagnosis of 0.7; because the ratio declines with age, this cutoff value may be artificially low for younger individuals, and artificially high for elderly individuals. NHANES III includes the CI for age and thus can identify patients with obstructive disease accounting for expected age changes. For these studies, the FEV1/SVC (slow VC) ratio is used because patients with more advanced disease may be predisposed to dynamic airway collapse that may falsely elevate the FEV1/FVC, 29 and thus appear restricted disease rather than obstructed. Consistent with this, all of patients identified by lower ratio using SVC had more advanced disease (with median FEV1% predicted of 37.5% as compared with the 46% median of the total cohort). Thus, NHANES III equations better identified patients with BOS, capturing patients in an earlier phase of disease, and correctly classifying those who might have received a diagnosis of obstruction due solely to age-related changes in normative values, or masked by advanced air trapping. Although differences in identification of obstruction were identified by ethnicity in prior studies, the predominance of Caucasians in our study precluded evaluation by ethnicity. 19 Two-minute walk velocity 14 was not significantly correlated with FEV1 calculated by either reference equation. This may be because either this test is influenced by many other factors or because 2-min walk velocity is insensitive to evaluate the influence of BOS on patient endurance. There was a suggestion that the FEV1 assessment by NHANES III may better predict oxygen requirement although small numbers precluded comprehensive evaluation. However, our data do suggest that the FEV1% predicted calculated with NHANESIII associate better with survival than FEV1% calculated with older equations.
These data may have implications for future studies in BOS. Recent investigations have improved our understanding of risk factors for BOS progression and offered potential novel insights for new intervention trials including the potential for immunomodulation by azithromycin, extracorporeal photopheresis, pulsed steroid therapy and rapamycin. [30] [31] [32] [33] [34] [35] [36] Prospective trials will provide the best data to understand both the ongoing immune dysregulation in BOS and the best potential agents to abate disease. Our data may have important implications for standardization of entry criteria and description of BOS severity, conferring that it would be important to use a single reference equation across sites and that NHANESIII may be better than older equations. In addition, for clinical care of these patients, predicting the need for oxygen supplementation and mortality is crucial, as these patients may benefit from more frequent evaluations or may be selected to receive additional high-risk therapies in an effort to halt a disease process with a high likelihood of imminent death.
These data will hopefully add to previously published data to improve outcomes for our patients through enhanced collaboration with pulmonary medicine colleagues, standardization of definitions of BOS and the tools to identify these patients. Barriers to early diagnosis of BOS include the time to complete full cGVHD analyses, 37 lack of PFT monitoring (recommended every 3 months for patients with newly diagnosed cGVHD), and as we propose here, interpretation of results with older equations. Although incorporation of NHANES III into PFT laboratories is both a cost and an investment (given that established protocols will have been using other equations), these should be weighed thoughtfully against the potential benefit of early and more accurate diagnosis. As most of current understanding of BOS emerged from the lung transplant field, hopefully, these data will generate collaborative discussions among pulmonologists and HSCT physicians to begin more assertively address these issues and permit enhanced studies in the future.
In conclusion, these data demonstrate that NHANES III reference equations identify more patients with BOS after HSCT and better predict disease severity, possibly leading to an earlier and more accurate clinical diagnosis of BOS and improved prediction of survival. As HSCT is a curative therapy for many patients with lifethreatening disease, it is imperative to move forward to improve the morbidity and mortality of BOS, one of the most serious transplant complications. Our findings may have important implications for the characterization of disease severity and the design of clinical trials for patients with BOS after HSCT.
